[Purpose] This study aimed to investigate the changes in blood pressure due to mild hyperbaric oxygen at 1.3 atmospheres absolute with approximately 30% oxygen. [Participants and Methods] Ten healthy adults participated in two trials: the control (1 atmosphere absolute with 20.9% oxygen) and the mild hyperbaric oxygen (1.3 atmospheres absolute with approximately 30% oxygen) trials. All participants were exposed to either the control or mild hyperbaric oxygen conditions in a chamber for 45 min on each experiment day. [Results] A lower heart rate and higher peripheral oxygen saturation were observed after exposure in the mild hyperbaric oxygen trial than those in the control trial. After exposure, the change in ratios from the premeasurement of systolic and diastolic blood pressure in the mild hyperbaric oxygen trial was more than that in the control trial, despite no change in the absolute blood pressure values between the two groups during the exposure. [Conclusion] This is the first study to reveal that mild hyperbaric oxygen exposure might be a control method for chronic hypotension. In addition, these results suggest that people with hypertension might require some attention when using mild hyperbaric oxygen.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057685 | PMC |
http://dx.doi.org/10.1589/jpts.34.360 | DOI Listing |
Int Marit Health
January 2025
National Centre for Hyperbaric Medicine, Institute of Maritime and Tropical Medicine in Gdynia, Medical University of Gdansk, Poland.
Medical hyperbaric sessions for Hyperbaric Oxygen Therapy, conducted at 2.4-2.5 ATA for 80 to 120 minutes, expose staff to increased risk of DCS due to the inhalation of compressed air, which increases gas solubility in body fluids as per Henry's Law.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
School of Medicine, Guizhou University, Guiyang 550025, China; NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China. Electronic address:
Introduction: Depression negatively impacts the prognosis of various cancers, including lung cancer, by influencing antitumor immune responses and impairing immune cell function. Antidepressants may modulate the tumor immune microenvironment, enhancing immunotherapy efficacy. However, the specific mechanisms remain unclear.
View Article and Find Full Text PDFToxicol Ind Health
December 2024
Department of Emergency, Zhoushan Hospital of Zhejiang Province, Zhoushan, China.
This study investigated the etiology, clinical features, and management of acute hydrogen sulfide (HS) poisoning in Zhoushan. A retrospective analysis was conducted on 10 patients admitted to our hospital between August and September 2023 due to two incidents of acute HS poisoning. The first incident involved fishermen working in a fishing cabin (6 patients), while the second involved sanitation workers during sewer maintenance (4 patients).
View Article and Find Full Text PDFDiving Hyperb Med
December 2024
Department of Kinesiology, Faculty of Medicine, Université Laval, Québec, Canada.
Introduction: Hyperbaric oxygen treatment (HBOT) is considered definitive treatment for decompression illness. Delay to HBOT may be due to dive site remoteness and limited facility availability. Review of cases may help identify factors contributing to clinical outcomes.
View Article and Find Full Text PDFCureus
September 2024
Department of Neuro-Physiotherapy, Ravi Nair Physiotherapy College, Datta Meghe Institute of Higher Education & Research (Deemed to be University), Wardha, IND.
Children between the ages of one and 18 are at a heightened risk of death and impairment due to traumatic brain injury (TBI). TBI can be deadly and is usually categorized as mild, moderate, or severe according to the Glasgow Coma Scale (GCS). For individuals with a TBI and an abnormal GCS, the preferred modality is non-contrast CT of the head.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!